Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.

Alberto GaraventaUlrike PötschgerDominique Valteau-CouanetRoberto LukschVictoria CastelMartin ElliottShifra AshGodfrey Chi Fung ChanGeneviève LaureysMaja Popovic-BeckKim VettenrantaWalentyna BalwierzHenrik SchroederCormac OwensMaja CesenVassilios PapadakisToby N Trahair Gudrun Schleiermacher Peter F AmbrosStefania SorrentinoAndrew D J Pearson Ruth Lydia Ladenstein

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)

No difference in outcome was observed between rCOJEC and MSKCC-N5; however, acute toxicity was less with rCOJEC, and therefore rCOJEC is the preferred induction regimen for International Society of Pediatric Oncology European Neuroblastoma Group.

Keyphrases

palliative care
liver failure
oxidative stress
respiratory failure
stem cells
drug induced
intensive care unit
young adults
hepatitis b virus
mesenchymal stem cells
acute respiratory distress syndrome
smoking cessation
replacement therapy
childhood cancer
mechanical ventilation